I’ve always been an overachiever – someone who puts their mind to something and delivers more than was expected, someone who strives for greatness. I never wanted to be an…
IDEAYA Biosciences and Servier announced promising Phase 2/3 trial results for darovasertib, a selective PKC inhibitor, combined with crizotinib in the treatment of metastatic uveal melanoma. According to BioSpace.com, the…
As reported on Healthline, a man in Norway has entered sustained HIV remission following a stem cell transplant, becoming one of a small number of individuals worldwide to achieve what…
Two University of Michigan professors, Jolanta Grembecka and her husband Tomasz Cierpicki, created the newly approved leukemia drug ziftomenib. Its recent FDA approval offers new hope for patients. The approval,…
Sarepta Therapeutics has announced a significant regulatory milestone in its efforts to secure permanent FDA approval for two breakthrough Duchenne muscular dystrophy (DMD) treatments. As reported by BusinesWire.com, the company…
Editor's Note: Patient Worthy is honored to share this article, originally submitted by Camille Johnson. For chronic disease patients living with rare conditions and long-term symptoms, whole-body health challenges can…
As reported on Cardiovascular Business, new long-term findings presented at the American College of Cardiology (ACC) 2026 meeting provide compelling evidence that early and continuous treatment with acoramidis (Attruby) confers…
A pivotal study recently published in the journal Gero Science has revealed new insights into how individual brain regions age and why some are more severely disrupted by Alzheimer's disease…
A decade of accumulated clinical experience with nusinersen has culminated in a significant regulatory advancement. According to Pharma Times Online, Biogen's newly approved high-dose Spinraza regimen represents a thoughtful evolution…
As reported by Manila Times, Ocular Therapeutix has released additional one‑year results from its Phase 3 SOL‑1 trial evaluating AXPAXLI (formerly OTX‑TKI) for the treatment of neovascular age‑related macular degeneration…
As reported on BioPharmaDive, several biopharmaceutical companies reported notable clinical and regulatory developments this week, with investor response reflecting growing confidence in both late‑stage pipelines and lifecycle management strategies. United…
Researchers have demonstrated substantial therapeutic benefits for brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, in adults with dermatomyositis, according to findings from a Phase 3 clinical trial published…
Akebia Therapeutics has initiated clinical development of a new investigational therapy aimed at preventing or treating acute kidney injury (AKI) associated with cardiac surgery. The company announced that the first…
Triple negative breast cancer, the most aggressive form of breast cancer, is under attack. Adelaide University researchers, led by Dr. Theresa Hinkey, report that unlike chemotherapy, the pill only targets…
CatalYm has initiated patient enrollment in the GDFATHER-HCC-01 trial, a Phase 2b study investigating visugromab as part of a combinatorial treatment strategy for patients with unresectable or metastatic hepatocellular carcinoma…
Phase 2 data suggest meaningful skin improvement and an acceptable safety profile As reported on Healio, litifilimab, an investigational therapy developed by Biogen, demonstrated encouraging efficacy and tolerability in patients…
As reported on Inside Precision Medicine, Researchers at Stanford have created a new urine test that helps doctors understand how well bladder cancer treatments are working. Usually, bladder cancer is…
Chugai Pharmaceutical Co., Ltd. announced that Roche has made the strategic decision to discontinue clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin antibody, for two neuromuscular conditions: spinal muscular…
As reported on PharmaBiz, Amgen has announced encouraging topline results from a phase 3 clinical trial evaluating a subcutaneous formulation of Tepezza (teprotumumab-trbw) for adults with moderate-to-severe active thyroid eye…
Most of us have heard of the fight-or-flight stress response. It becomes activated when we believe there is a chance we can outfight or outrun real or perceived danger and…
Telomir Pharmaceuticals has taken a significant step forward in the development of a novel therapeutic agent for one of oncology's most challenging cancers. As reported by Pharmaceutical Technology, the company…
I have battled several autoimmune and neurological conditions that are triggered by food and other factors for over 50 years. It took most of my life to reach not one,…
The traditional model of HIV care has long centered on one fundamental requirement: patients must take medication every single day, without fail. Yet this model increasingly conflicts with the complex…
As reported by GlobeNewsWire, results from the Phase 3 VALOR trial evaluating brepocitinib in adults with dermatomyositis have been published in the New England Journal of Medicine, marking a significant…
Editor's Note: Patient Worthy is pleased to share the final part in a series of excerpts by Dana Langston. Chapter 36: Holding the Line Knowing the surgery won't happen until…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
